
Citation: Michiro Muraki. Development of expression systems for the production of recombinant human Fas ligand extracellular domain derivatives using Pichia pastoris and preparation of the conjugates by site-specific chemical modifications: A review[J]. AIMS Bioengineering, 2018, 5(1): 39-62. doi: 10.3934/bioeng.2018.1.39
[1] | Zhiyan Ding, Hichem Hajaiej . On a fractional Schrödinger equation in the presence of harmonic potential. Electronic Research Archive, 2021, 29(5): 3449-3469. doi: 10.3934/era.2021047 |
[2] | Messoud Efendiev, Vitali Vougalter . Linear and nonlinear non-Fredholm operators and their applications. Electronic Research Archive, 2022, 30(2): 515-534. doi: 10.3934/era.2022027 |
[3] | Bidi Younes, Abderrahmane Beniani, Khaled Zennir, Zayd Hajjej, Hongwei Zhang . Global solution for wave equation involving the fractional Laplacian with logarithmic nonlinearity. Electronic Research Archive, 2024, 32(9): 5268-5286. doi: 10.3934/era.2024243 |
[4] | Huali Wang, Ping Li . Fractional integral associated with the Schrödinger operators on variable exponent space. Electronic Research Archive, 2023, 31(11): 6833-6843. doi: 10.3934/era.2023345 |
[5] | Tao Zhang, Tingzhi Cheng . A priori estimates of solutions to nonlinear fractional Laplacian equation. Electronic Research Archive, 2023, 31(2): 1119-1133. doi: 10.3934/era.2023056 |
[6] | Hui Jian, Min Gong, Meixia Cai . Global existence, blow-up and mass concentration for the inhomogeneous nonlinear Schrödinger equation with inverse-square potential. Electronic Research Archive, 2023, 31(12): 7427-7451. doi: 10.3934/era.2023375 |
[7] | Xiaoming An, Shuangjie Peng . Multi-peak semiclassical bound states for Fractional Schrödinger Equations with fast decaying potentials. Electronic Research Archive, 2022, 30(2): 585-614. doi: 10.3934/era.2022031 |
[8] | Shasha Bian, Yitong Pei, Boling Guo . Numerical simulation of a generalized nonlinear derivative Schrödinger equation. Electronic Research Archive, 2022, 30(8): 3130-3152. doi: 10.3934/era.2022159 |
[9] | Ibtissam Issa, Zayd Hajjej . Stabilization for a degenerate wave equation with drift and potential term with boundary fractional derivative control. Electronic Research Archive, 2024, 32(8): 4926-4953. doi: 10.3934/era.2024227 |
[10] | Yang Liu, Wenke Li . A family of potential wells for a wave equation. Electronic Research Archive, 2020, 28(2): 807-820. doi: 10.3934/era.2020041 |
In this paper, we examine the following Schrödinger equation:
$ {iψt=(−Δ)sψ+|x|2ψ−|ψ|2σψinRN×[0,∞),ψ(0,x)=ψ0(x)∈Hs(RN), $ | (1) |
where
$ Hs(RN):={u∈L2(RN):∫RN∫RN|u(x)−u(y)|2|x−y|N+2sdydx<∞}. $ |
with
$ ‖u‖Hs(RN)=√∫RN∫RN|u(x)−u(y)|2|x−y|N+2sdydx+∫RN|u(x)|2dx. $ |
The fractional Laplacian
$ (−Δ)su(x)=F−1[|ξ|2s[u]], s>0. $ | (2) |
For the Cauchy problem, formally we have two conserved quantities [17] by multiplying the conjugate of
$ M(t)=||ψ(⋅,t)||2:=∫RN|ψ(x,t)|2dx≡M(0) $ | (3) |
and the total energy:
$ E(t)=∫RN[Re(ψ∗(x,t)(−Δ)sψ)+|x|2|ψ|2−1σ+1|ψ(x,t)|2(σ+1)]dx≡E(0). $ | (4) |
In recent years, a great attention has been focused on the study of problems involving the fractional Laplacian, which naturally appears in obstacle problems, phase transition, conservation laws, financial market. Nonlinear fractional Schrödinger equations (FNLS) have been proposed by [20,19,9] in order to expand the Feynman path integral, from the Brownian like to the Lévy like quantum mechanical paths. The stationary solutions of fractional nonlinear Schrödinger equations have also been intensively studied due to their huge importance in nonlinear optics and quantum mechanics [20,19,14,12]. The most interesting solutions have the special form:
$ ψ(x,t)=e−iλtu(x),λ∈R,u(x) isasmoothfunction. $ | (5) |
They are called the standing waves. These solutions reduce (1) to a semilinear elliptic equation. In fact, after plugging (5) into (1), we need to solve the following equation
$ (−Δ)su(x)+|x|2u(x)−|u(x)|2σu(x)=λu(x)inRN. $ | (6) |
The case
In this paper, we mainly focus on the solutions to (6). To the best of our knowledge, our results are new and will open the way to solve other classes of fractional Schrödinger equations. This paper has two main parts: In the first part, we address the existence of standing waves through a particular variational form, whose solutions are called ground state solutions. We prove the existence of ground state solutions (Theorem 2.1), and show some qualitative properties like monotonicity and radiality (Lemma 4). We also show that the ground state solutions are orbitally stable (Def 4.2, Theorem 2.2) if we have the uniqueness of the solutions for the Cauchy problem (1) (Theorem 4.3). We have also addressed the critical case
The main difficulty of constructing ground state solutions comes from the lack of compactness of the Sobolev embeddings for the unbounded domain
The paper is organized as follows. In section 2, we give our main results about the existence of ground state solutions and the orbital stability of standing waves. In section 3, we provide proof of existence. Then, in section 4, we discuss the orbital stability. In section 5, we use Split-Step Fourier Spectral method to solve (1) numerically. In section 6, instead of using common iterative Newton's method, we use the NGF method to find ground states when
We use a variational formulation to examine the solution to (6). First, note that if
$ J(u)=12‖∇su‖2L2(RN)+12∫RN|x|2|u|2dx−12σ+2∫RN|u|2σ+2dx, $ | (7) |
where
$ \|\nabla_{s}u\|_{L^{2}({\mathbb{R}^{N}})}^{2} = C_{N, s}\int_{\mathbb{R}^{N}}\int_{\mathbb{R}^{N}}\frac{|u(x)-u(y)|^{2}}{|x-y|^{N+2s}}dxdy, $ |
with some normalization constant
We can derive (7) by multiplying smooth enough test function
$ Ic=inf{J(u):u∈Sc}, $ | (8) |
with
$ Sc={u∈Σs(RN):∫RN|u|2dx=c2}, $ | (9) |
where
$ Σs(RN)={u∈Hs(RN):‖u‖Σs(RN):=√‖u‖2L2(RN)+‖∇su‖2L2(RN)+‖xu‖2L2(RN)<∞}. $ | (10) |
is a Hilbert space, with corresponding natural inner product.
We claim that for each minimizer
$ J∗(u)=J(u)+λ(‖u‖2L2(RN)−c2). $ | (11) |
The minimizer to problem (8) must be the critical point of (11), satisfying:
$ ∂J∗(u)∂u=0 $ | (12) |
and
$ ∂J∗(u)∂λ=0, $ | (13) |
where (12) implies (6) and (13) implies (9). In this paper, we will mainly focus on the minimizers of problem (8). The following theorem discusses the existence of such minimizers.
Theorem 2.1. If
Remark 1. There were some works considering standing waves for fractional nonlinear Schrödinger equation with different potential enery and nonlinearity terms. In [6], the authors focus on the case where the nonlinearity term is asymptotically linear with
Remark 2. The condition
After we construct the ground state solutions, we further investigate their stability. By the definition of (5), the ground state solution moves around a circle when the time changes. Therefore we consider and prove the orbital stability of ground state solution (Def 4.2).
Theorem 2.2. Suppose that
In this section, we will establish the existence of ground state solutions of (6), the main difficulty comes from the lack of compactness of the Sobolev embeddings. Usually, at least when the potential in (1) is radially symmetric and radially increasing, such difficulty is overcome by considering the appropriate function space. More precisely, we have
Lemma 3.1. Let
Proof. First, when
$ ∫|x|≥R|u|2dx≤|R|−2∫|x|≥R|x|2|u|2dx<|R|−2‖u‖2Σs(RN) $ | (14) |
By the classical Sobolev embedding theorem, for any fixed
Second, for
$ ‖u‖pLp(RN)≤K‖u‖1−θL2(RN)‖∇su‖θL2(RN)≤K‖u‖1−θL2(RN)‖u‖θΣs(RN), $ | (15) |
for some positive constant
Then we have a lemma showing the existence of
Lemma 3.2. If
Proof. First, we prove that
$ ‖u‖L2σ+2(RN)≤K‖u‖1−θL2(RN)‖∇su‖θL2(RN), $ | (16) |
for some positive constant
On the other hand, let
$ ‖u‖(2σ+2)(1−θ)L2(RN)‖∇su‖θ(2σ+2)L2(RN)≤1pϵp‖∇su‖pθ(2σ+2)L2(RN)+1qϵq‖u‖q(1−θ)(2σ+2)L2(RN). $ | (17) |
Combining (16) and (17), we obtain that for any
$ ∫RN|u(x)|2σ+2dx≤ϵpK2σ+2p‖∇su‖2L2(RN)+K2σ+2qϵqc2q(1−θ)(1+σ), $ | (18) |
where
Hence, from (18) we get:
$ J(u) $ | (19) |
$ =12‖∇su‖2L2(RN)+12∫RN|x|2|u|2dx−12σ+2∫RN|u|2σ+2dx $ | (20) |
$ ≥12‖∇su‖2L2(RN)+12∫RN|x|2|u|2dx $ | (21) |
$ −12σ+2(ϵpK2σ+2p‖∇su‖2L2(RN)+K2σ+2qϵqc2q(1−θ)(1+σ)) $ | (22) |
$ ≥(12−ϵpK2σ+22p(σ+1))‖∇su‖2L2(RN)+12∫RN|x|2|u|2dx−K2σ+2c2q(1−θ)(1+σ)2q(1+σ)ϵq. $ | (23) |
Then we choose
Now, we can use compactness (Lemma 3.1) and boundedness (Lemma 3.2) to prove our existence Theorem 2.1.
Proof. Let
Since
On the other hand, thanks to the lower semi-continuity, we have
$ \|xu\|_{L^2({\mathbb{R}^{N}})}+\|\nabla_{s}u\|_{L^2({\mathbb{R}^{N}})}\leq \liminf\limits_{n\rightarrow \infty} \|\nabla_{s}u_{n}\|_{L^2({\mathbb{R}^{N}})}+\|xu_n\|_{L^2({\mathbb{R}^{N}})}\, . $ |
Therefore
$ Ic≤J(u)≤lim infn→∞J(un)=Ic, $ | (24) |
which yields that
The second step consists of constructing a nonnegative, radial, and radially decreasing minimizer. First, we note that:
$ ‖∇s|u|‖L2(RN)≤‖∇su‖L2(RN), $ | (25) |
which implies that
$ meas\left\{x \in \mathbb{R}^{N}: \left|u(x)\right| > \mu\right\} = meas\left\{x \in \mathbb{R}^{N}: u^{\ast}(x) > \mu\right\}\;{\rm{\;for\;any\;}}\;\mu > 0. $ |
It is well-known [15] that
$ {∫RN|u|2σ+2dx=∫RN|u∗|2σ+2dx,∫RN|u|2dx=∫RN|u∗|2dx,∫RN|x|2|u∗|2dx≤∫RN|x|2|u|2dx. $ | (26) |
Besides, from [3] Lemma 6.3, we also have
$ ‖∇su∗‖L2(RN)≤‖∇su‖L2(RN). $ | (27) |
Combining (26) and (27), we obtain that
$ \mathcal{J}(|u|^{\ast})\leq \mathcal{J}(|u|)\leq\mathcal{J}(u), \quad {\rm{for\;any}}\ u\in\Sigma_s(\mathbb{R}^N)\, . $ |
Remark 3. By (24) and the weakly convergence, we can also see that:
$ ‖xu‖L2(RN)+‖u‖L2(RN)+‖∇su‖L2(RN)=limn→∞‖∇sun‖L2(RN)+‖un‖L2(RN)+‖xun‖L2(RN), $ |
which implies that there is a minimizing subseqence
Remark 4. If
$ Ic=J(u)=J(|u|)=J(|u|∗). $ | (28) |
By (27) and (28), we obtain that
$ ‖∇su‖L2(RN)=‖∇s|u|‖L2(RN), $ | (29) |
which implies that
$ ∫RN|x|2(|u|∗)2dx=∫RN|x|2|u|2dx. $ | (30) |
which further implies
In this section, we will deal with the orbital stability of the ground state solutions. Let us introduce the appropriate Hilbert space:
$ ˜Σs(RN):={ω=u+iv:(u,v)∈Σs(RN)×Σs(RN)}, $ |
equipped with the norm
In term of the new coordinates, the energy functional reads
$ ˜J(ω)=12‖∇sω‖2L2(RN)+12∫RN|x|2|ω(x)|2dx−12σ+2∫RN|ω|2σ+2dx, $ |
where
Then, for all
$ ˜Ic=inf{˜J(ω),ω∈˜Sc}, $ |
where
$ ˜Sc={ω∈˜Σs(RN),∫RN|ω(x)|2dx=c2}. $ |
We also introduce the following sets
$ Oc={u∈Sc:Ic=J(u)},˜Oc={ω∈˜Sc:˜Ic=˜J(ω)}. $ |
Proceeding as in [4,16], we have the following lemma:
Lemma 4.1. If
(i) The energy functional
(ii) There exists a constant
$ ‖J′(u)‖Σ−1s(RN)≤C(‖u‖Σs(RN)+‖u‖2σ+1Σs(RN)),‖˜J′(ω)‖Σ−1s(RN)≤C(‖ω‖Σs(RN)+‖ω‖2σ+1Σs(RN)). $ |
(iii) All minimizing sequences for
(iv) The mappings
(v) Any minimizing sequence of
(vi) For any
$ Ic=˜Ic. $ |
Proof. (i) We follow the steps of Proposition 2.3 [16] by choosing
$ −∫RN|u(x)|2σu(x)v(x)dx $ |
is of class
(ii) From (i),
$ ⟨J′(u),v⟩=CN,S∫RN∫RN|u(x)−u(y)||v(x)−v(y)||x−y|N+2sdxdy+∫RN|x|2u(x)v(x)dx−∫RN|u(x)|2σu(x)v(x)dx. $ |
For the last term, by Hölder's inequality, we have
$ ∫RN|u(x)|2σu(x)v(x)dx≤‖u‖2σ+1L2σ+2(RN)‖v‖L2σ+2(RN). $ |
Therefore, there exists
$ ‖J′(u)‖Σ−1s(RN)≤C(‖u‖Σs(RN)+‖u‖2σ+1Σs(RN)). $ |
(iii) This is a direct result of Lemma 3.2.
(iv) Let
$ Icn≤J(un)<Icn+1n. $ | (31) |
From (iii), there exists a constant
$ \|u_{n}\|_{\Sigma_{s}(\mathbb{R}^{N})}\leq C_{1}, \;\;\forall\;n\in \mathbb{N}. $ |
Setting
$ vn∈Scand‖un−vn‖Σs(RN)=|1−ccn|‖un‖Σs(RN)≤C1|1−ccn|, $ |
which implies that
$ ‖un−vn‖Σs(RN)≤C1+1fornlargeenough. $ | (32) |
We deduce by part (ii) that there exists a positive constant
$ ‖J′(u)‖Σ−1s(RN)≤K,forallu∈Σs(RN)with‖u‖Σs(RN)≤2C1+1. $ | (33) |
By (32) and (33), we get that
$ |J(vn)−J(un)|=|∫10ddtJ(tvn+(1−t)un)dt|≤sup‖u‖Σs(RN)≤2C1+1‖J′(u)‖Σ−1s(RN)‖vn−un‖Σs(RN)≤KC1|1−ccn|. $ | (34) |
Then, from (31) and (34), we obtain that
$ Icn≥J(un)−1n≥J(vn)−KC1|1−ccn|−1n≥Ic−KC1|1−ccn|−1n $ |
Combining this with the fact that
$ lim infn→∞Icn≥Ic. $ | (35) |
Now, from Lemma 3.2 and by the definition of
$ ‖un‖Σs(RN)≤C2andlimn→∞J(un)=Ic. $ |
Set
$ \|v_{n}-u_{n}\|_{\Sigma_{s}(\mathbb{R}^{N})}\leq C_{2}\left|1-\frac{c_{n}}{c}\right|\;\;{\rm{and}}\;\;| \mathcal{J}(v_{n})- \mathcal{J}(u_{n})|\leq L\, C_{2}\left|1-\frac{c_{n}}{c}\right|. $ |
Combining this with (31), we obtain that
$ \mathcal{I}_{c_{n}}\leq \mathcal{J}(v_{n})\leq \mathcal{J}(u_{n})+L\, C_{2}\left|1-\frac{c_{n}}{c}\right|. $ |
Since
$ lim supn→∞Icn≤Ic. $ | (36) |
It follows from (35) and (36) that
$ \lim\limits_{n\rightarrow \infty}\mathcal{I}_{c_{n}} = \mathcal{I}_{c}. $ |
(v) This is a direct result of Remark 3.
(vi) First, we can see
$ \widetilde{\mathcal{J}}(\omega) = \mathcal{J}(\omega)\, , $ |
which implies that
$ Ic≥˜Ic. $ | (37) |
Second, for any
$ \|\nabla_{s}\omega\|^{2}_{L^2(\mathbb{R}^{N})}\geq\|\nabla_{s}|\omega|\|^{2}_{L^2(\mathbb{R}^{N})}, $ |
which implies that
$ \widetilde{\mathcal{J}}(\omega)\geq \widetilde{\mathcal{J}}(|\omega|) = \mathcal{J}(\omega)\geq \mathcal{I}_c, \quad \forall\omega\in\widetilde{\Sigma}_s(\mathbb{R}^{N}), $ |
and
$ ˜Ic≥Ic. $ | (38) |
Combining (37) and (38), we finally have
Now, for a fixed
Definition 4.2 We say that
●
● For all
$ \|\omega_0-\psi_{0}\|_{\widetilde{\Sigma}_{s}(\mathbb{R}^{N})} < \delta\;\Longrightarrow\; \inf\limits_{\omega\in\widetilde{\mathcal{O}}_{c}}\|\omega-\psi\|_{\widetilde{\Sigma}_{s}(\mathbb{R}^{N})} < \varepsilon, $ |
where
If
Theorem 4.3. Suppose that
$ ‖ψ(t,.)‖L2(RN)=‖ψ0(t,.)‖L2(RN)and˜J(ψ(t,.))=˜J(ψ0(t,.)), $ | (39) |
then
Proof. The proof is by contradiction: Suppose that
$ infZ∈˜Oc‖Φn(tn,.)−Z‖˜Σs(RN)≥ε $ | (40) |
for some sequence
Let
$ ‖Φn0‖L2(RN)→cand˜J(Φn0)→˜Ic, n→∞. $ |
Thus, we deduce from (39) that
$ ‖ωn‖L2(RN)=‖Φn0‖L2(RN)→cand˜J(ωn)=˜J(Φn0)→˜Ic, n→∞. $ | (41) |
Since
$ un⇀u,vn⇀vandlim infn→∞‖∇sun‖L2(RN)+‖∇svn‖L2(RN)exists. $ | (42) |
Now, by a straightforward computation, we obtain that
$ ˜J(ωn)−˜J(|ωn|)=12‖∇sωn‖2L2(RN)−12‖∇s|ωn|‖2L2(RN)≥0, $ | (43) |
which implies that
$ ˜Ic=limn→∞˜J(ωn)≥lim supn→∞J(|ωn|). $ |
Besides, by (41),
$ ‖ωn‖2L2(RN)=‖|ωn|‖2L2(RN)=c2n→c2. $ |
It follows from Lemma 4.1 that we have
$ lim infn→∞J(|ωn|)≥lim infn→∞Icn=Ic. $ |
Hence
$ ˜Ic=limn→∞˜J(ωn)=limn→∞J(|ωn|)=Ic. $ | (44) |
It follows from (42), (43) and (44) that
$ limn→∞‖∇sun‖2L2(RN)+‖∇svn‖2L2(RN)−‖∇s(u2n+v2n)12‖2L2(RN)=0, $ |
which is equivalent to say that
$ limn→∞‖∇swn‖2L2(RN)=limn→∞‖∇s|wn|‖2L2(RN). $ | (45) |
The boundedness of
$ |ωn|→φinΣs(RN)and‖φ‖L2(RN)=cwithJ(φ)=Ic. $ | (46) |
Next, let us prove
$ u_{n}\longrightarrow u\;{\rm{\;and\;}}\;v_{n}\longrightarrow v\;{\rm{\;in\;}}\;L^{2}(B(0, R))\;{\rm{for\;all}}\;R > 0\, . $ |
Since
$ (u_{n}^{2}+v_{n}^{2})^{\frac{1}{2}}\longrightarrow (u^{2}+v^{2})^{\frac{1}{2}}\;\;{\rm{in}}\;\;L^{2}(B(0, R))\, . $ |
But
$ (u^{2}+v^{2})^{\frac{1}{2}} = |\omega| = \varphi\, . $ |
This further implies that
$ ‖ω‖L2(RN)=‖φ‖L2(RN)=c,‖ω‖L2σ+2(RN)=‖φ‖L2σ+2(RN). $ | (47) |
and
$ 12∫RN|x|2|ω|2dx−12σ+2∫RN|ω|2σ+2dx=12∫RN|x|2|φ|2dx−12σ+2∫RN|φ|2σ+2dx=limn→∞12∫RN|x|2|ωn|2dx−12σ+2∫RN|ωn|2σ+2dx. $ | (48) |
Additionally, by the lower semi-continuity, we further have
$ ‖∇ω‖2L2(RN)≤lim infn→∞‖∇ωn‖2L2(RN). $ | (49) |
Combining (48) with (49) and
$ ˜Ic≤˜J(ω)≤limn→∞˜J(ωn)=˜Ic, $ |
which implies that
$ ω∈˜Ocand‖∇sω‖2L2(RN)=limn→∞‖∇sωn‖2L2(RN). $ | (50) |
Finally, by (46), (47), and (50), we obtain that
$ ωn→ωin˜Σs(RN), $ |
which contradicts to (40).
In this section, we consider numerical methods to solve (1) and introduce the Split-Step Fourier Spectral method.
First, we truncate (1) into a finite computational domain
$ {iψt=(−Δ)sψ+|x|2ψ−|ψ|2σψ, t>0,ψ(0,x)=ψ0(x), $ | (51) |
for
Let
$ (xj)n=−L+(j)nh, 1≤n≤N, $ | (52) |
where
Denote
$ ψ(xj,t)=∑k∈K^ψk(t)exp(iμkxj), $ | (53) |
where
Now, we introduce the Split-step Fourier Spectral method. The main idea of this method is to solve (51) in two splitting steps from
$ iψt=|x|2ψ−|ψ|2σψ, $ | (54) |
$ iψt=(−Δ)sψ. $ | (55) |
First, by multiplying
$ iψt=|x|2ψ−|ψ(x,tn)|2σψ. $ | (56) |
Second, taking Fourier transform on both sides of (55), we obtain that
$ id^ψk(t)dt=|μk|2s^ψk(t). $ | (57) |
We use the second order Strang splitting method with (56) and (57) as follows:
$ ψn,1j=ψnjexp(−i(|xj|2−|ψnj|2σ)τ/2) $ | (58) |
$ ψn,2j=∑k∈K^ψn,1kexp(−i|μk|2sτ)exp(iμkxj) $ | (59) |
$ ψn+1j=ψn,2jexp(−i(|xj|2−|ψn,2j|2σ)τ/2) $ | (60) |
where
$ ψ0j=ψ0(xj) $ | (61) |
This method has spectral order accuracy in space and second order in time. Similar to [8], this method preserves discrete mass corresponding to (3) defined as
$ Mn=(hN∑j|ψnj|2)1/2. $ | (62) |
To find ground state solutions, we have to solve the following equation corresponding to
$ (−Δ)su+|x|2u−|u|2σu=λu x∈RN. $ | (63) |
As discussed previously, for
Thus, for a given sequence of time
$ ∂u∂t=−∂E(u)∂u $ |
and project it onto
$ {∂˜u∂t=−(−Δ)s˜u−|x|2˜u+|˜u|2σ˜u,tn<t<tn+1,˜u(x,tn)=u(n)(x),u(n+1)(x)=c˜u(x,tn+1)||˜u(⋅,tn+1)||L2(RN),. $ |
Here, we use semi-implicity time discretization scheme:
$ {˜u(n+1)−˜u(n)Δt=−(−Δ)s˜u(n+1)−|x|2˜u(n+1)+|˜u(n)|2σ˜u(n+1),tn<t<tn+1,˜u(x,tn)=u(n)(x),u(n+1)(x)=c˜u(n+1)(x)||˜u(n+1)(⋅)||L2(RN), $ |
with
$ δsxu|j=∑k∈K|μk|2sexp(iμkxj) $ |
to discretize fractional Laplacian, where
In conlusion, in each step, we solve:
$ {˜u(n+1)j−u(n)jτ=−δsx˜u(n+1)|j−(|xj|2−|u(n)j|2σ)˜u(n+1)ju(n+1)j=c˜u(n+1)jMn, $ | (64) |
where
We need to notice that we can only solve (8) for
For
$ Lc=inf{K(u):u∈Tc} $ | (65) |
with
$ Tc={u∈Σs(RN):‖u‖L2σ+2(RN)=c}, $ |
$ K(u)=12‖∇su‖2L2(RN)+12∫RN|x|2|u(x)|2dx+ω2∫RN|u(x)|2dx, $ | (66) |
where
For
$ ∫RN|u(x)|2dx≤|R|−2∫|x|>R|x|2|u|2dx+∫|x|<R|u|2dx≤|R|−2∫|x|>R|x|2|u|2dx+CR,σ‖u‖2L2σ+2(RN), $ |
where
$ K(u)≥12‖∇su‖2L2+(12+ωR2)∫RN|x|2|u(x)|2dx+ω2CR,σc2>−∞ $ | (67) |
for
Now we see
$ K∗(u)=K(u)−λ2σ+2(‖u‖2σ+2L2σ+2(RN)−c2σ+2), $ |
then the critical points
$ (−Δ)su∗+|x|2u∗−λ|u∗|2σu∗+ωu∗=0,x∈RN $ | (68) |
by
$ K∗(u∗)=K(u∗)=λ2c2σ+2>0, $ | (69) |
which implies that
$ (−Δ)suω,c+|x|2uω,c−|uω,c|2σuω,c+ωuω,c=0,x∈RN, $ | (70) |
which means
Now, for
$ {˜u(n+1)j−u(n)jτ=−δsx˜u(n+1)|j−(|xj|2+u(n)j)˜u(n+1)ju(n+1)j=c˜u(n+1)jMn2σ+2, $ | (71) |
where
$ M^n_{2\sigma+2} = \left(h^N\sum\limits_{\textbf{j}}|u^n_{\textbf{j}}|^{2\sigma+2}\right)^{1/(2\sigma+2)} $ |
and
In this section, we show some numerical results, which can help us understand the ground state solution and also illustrate theoretical results. We have mainly investigated: 1. Ground state solutions with different
First, we solve (8) numerically by (64) in one dimension
Second, we use
By Theorem 2.1, we can obtain the existence of ground state solutions with
From figure 3a and figure 3b, it seems ground state solutions change continuously with
Then, we test another two things. The first is the relationship between the constrained minimal energy in (8) and
$ E(s)=hJ−1∑j=0[J/2−1∑l=−J/2|μl|2s|ˆul|2+|xj|2|uj|2−1σ+1|uj|2(σ+1)]. $ | (72) |
From figure 5a, we find the energy's dependence
Second, we test the relationship between
$ \lim\limits_{c\rightarrow 0}\lambda_c = \lambda_0\, . $ |
We also test this with
Up to now, we only consider the case with radially symmetrical potential. However, when the potential is not radially symmetric, we can still find a standing wave to (1) using (8). We tried cases where the potential has the form
First, we consider the case
$ D(s, t) = \frac{\|u^s(x, t)-\psi^s(x, t)\|_{\widetilde{\Sigma}_{s}(\mathbb{R})}}{\|u^s(x, t)\|_{\widetilde{\Sigma}_{s}(\mathbb{R})}}. $ |
We test initial conditions
Second, we try to obtain some numerical results when we touch the critical point
Finally, we test some simple time dynamics of FNLS, we let
[1] |
Takahashi T, Tanaka M, Inazawa J, et al. (1994) Human Fas ligand: gene structure, chromosomal location and species specificity. Int Immunol 6: 1567–1574. doi: 10.1093/intimm/6.10.1567
![]() |
[2] |
Linkermann A, Qian J, Lettau M, et al. (2005) Considering Fas ligand as a target for therapy. Expert Opin Ther Tar 9: 119–134. doi: 10.1517/14728222.9.1.119
![]() |
[3] |
Yonehara S, Ishii A, Yonehara M (1989) A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J Exp Med 169: 1747–1756. doi: 10.1084/jem.169.5.1747
![]() |
[4] |
Nagata S (1999) Fas ligand-induced apoptosis. Annu Rev Genet 33: 29–55. doi: 10.1146/annurev.genet.33.1.29
![]() |
[5] |
Bodmer JL, Schneider P, Tschopp J (2002) The molecular architecture of the TNF superfamily. Trends Biochem Sci 27: 19–26. doi: 10.1016/S0968-0004(01)01995-8
![]() |
[6] |
Timmer T, de Vries EG, de Jong S (2002) Fas receptor-mediated apoptosis: a clinical application? J Pathol 196: 125–134. doi: 10.1002/path.1028
![]() |
[7] |
Peter ME, Hadji A, Murmann AE (2015) The role of CD95 and CD95 ligand in cancer. Cell Death Differ 22: 549–559. doi: 10.1038/cdd.2015.3
![]() |
[8] |
Calmon-Hamaty F, Audo R, Combe B, et al. (2015) Targeting the Fas/FasL system in rheumatoid arthritis therapy: promising or risky? Cytokine 75: 228–233. doi: 10.1016/j.cyto.2014.10.004
![]() |
[9] |
Wu J, Wilson J, He J, et al. (1996) Fas ligand mutation in a patient with systemic lupus erythematosus and lymphoproliferative disease. J Clin Invest 98: 1107–1113. doi: 10.1172/JCI118892
![]() |
[10] |
Suda T, Takahashi T, Golstein P, et al. (1993) Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 75: 1169–1178. doi: 10.1016/0092-8674(93)90326-L
![]() |
[11] |
Nagata S (1997) Apoptosis by death factor. Cell 88: 355–365. doi: 10.1016/S0092-8674(00)81874-7
![]() |
[12] | Wajant H (2006) Fas signaling. New York: Springer Science+Business Media, 1–160. |
[13] |
Strasser A, Jost PJ, Nagata S (2009) The many roles of Fas receptor signaling in the immune system. Immunity 30: 180–192. doi: 10.1016/j.immuni.2009.01.001
![]() |
[14] | Bremer E (2013) Targeting of the tumor necrosis factor receptor superfamily for cancer immunotherapy. ISRN Oncol 2013: 371854. |
[15] |
Hsieh SL, Lin WW (2017) Decoy receptor 3: an endogenous immunomodulator in cancer growth and inflammatory reactions. J Biomed Sci 24: 39. doi: 10.1186/s12929-017-0347-7
![]() |
[16] |
Liu W, Ramagopal U, Cheng H, et al. (2016) Crystal structure of the complex of human FasL and its decoy receptor DcR3. Structure 24: 2016–2023. doi: 10.1016/j.str.2016.09.009
![]() |
[17] |
Muraki M (2012) Heterologous production of death ligands' and death receptors' extracellular domains: structural features and efficient systems. Protein Peptide Lett 19: 867–879. doi: 10.2174/092986612801619606
![]() |
[18] | Tanaka M, Suda T, Yatomi T, et al. (1997) Lethal effect of recombinant human Fas ligand in mice pretreated with Propionibacterium acnes. J Immunol 158: 2303–2309. |
[19] |
Muraki M (2006) Secretory expression of synthetic human Fas ligand extracellular domain gene in Pichia pastoris: influences of tag addition and N-glycosylation site deletion, and development of a purification method. Protein Expres Purif 50: 137–146. doi: 10.1016/j.pep.2006.08.006
![]() |
[20] |
Lu Y, Knol JC, Linskens MHK, et al. (2004) Production of the soluble human Fas ligand by Dictyostelium discoideum cultivated on a synthetic medium. J Biotechnol 108: 243–251. doi: 10.1016/j.jbiotec.2003.12.006
![]() |
[21] |
Luo Z, Xu Z, Zhuo S, et al. (2012) Production, purification and cytotoxity of soluble human Fas ligand expressed by Escherichia coli and Dictyostelium discoideum. Biochem Eng J 62: 86–91. doi: 10.1016/j.bej.2012.01.002
![]() |
[22] |
Sun KH, Sun GH, Tsai CY, et al. (2005) Expression, purification, refolding, and characterization of recombinant human soluble-Fas ligand from Escherichia coli. Enzyme Microb Tech 36: 527–534. doi: 10.1016/j.enzmictec.2004.11.013
![]() |
[23] | Muraki M (2014) Disulfide-bridged proteins with potential for medical applications: therapeutic relevance, sample preparation and structure-function relationships. Integr Mol Med 1: 38–56. |
[24] |
Holler N, Tardivel A, Kovacsovicsbankowski M, et al. (2003) Two adjacent trimeric Fas ligands are required for Fas signaling and formation of a death-inducing signaling complex. Mol Cell Biol 23: 1428–1440. doi: 10.1128/MCB.23.4.1428-1440.2003
![]() |
[25] |
Eisele G, Roth P, Hasenbach K, et al. (2011) APO010, a synthetic hexameric CD95 ligand, induces human glioma cell death in vitro and in vivo. Neuro-Oncology 13: 155–164. doi: 10.1093/neuonc/noq176
![]() |
[26] | Eisele G, Wolpert F, Decrey G, et al. (2013) APO010, a synthetic hexameric CD95 ligand, induces death of human glioblastoma stem-like cells. Anticancer Res 33: 3563–3571. |
[27] | Oncology venture: APO010, 2012. Available from: http://www.oncologyventure.com/pipeline/apo010/. |
[28] | ClinicalTrials.gov: ID NCT03196947, Safety and pharmacokinetics of rising doses of APO010 in relapsed/refractory multiple myeloma patients selected by DRP (SMR-3184). Available from: https://clinicaltrials.gov/ct2/show/NCT03196947?recrs=ab&cond=APO010&rank=1. |
[29] |
Daburon S, Devaud C, Costet P, et al. (2013) Functional characterization of a chimeric soluble Fas ligand polymer with in vivo anti-tumor activity. Plos One 8: e54000. doi: 10.1371/journal.pone.0054000
![]() |
[30] |
Samel D, Müller D, Gerspach J, et al. (2003) Generation of a FasL-based proapoptotic fusion protein devoid of systemic toxicity due to cell-surface antigen-resticted activation. J Biol Chem 278: 32077–32082. doi: 10.1074/jbc.M304866200
![]() |
[31] |
Bremer E, Ten CB, Samplonius DF, et al. (2008) Superior activity of fusion protein scFvRit:sFasL over cotreatment with rituximab and Fas agonists. Cancer Res 68: 597–604. doi: 10.1158/0008-5472.CAN-07-5171
![]() |
[32] |
Bremer E, Ten CB, Samplonius DF, et al. (2006) CD7-restricted activation of Fas-mediated apoptosis: a novel therapeutic approach for acute T-cell leukemia. Blood 107: 2863–2870. doi: 10.1182/blood-2005-07-2929
![]() |
[33] |
Chien MH, Chang WM, Lee WJ (2017) A Fas ligand (FasL)-fused humanized antibody against tumor-associated glycoprotein 72 selectively exhibits the cytotoxic effect against oral cancer cells with a low FasL/Fas ratio. Mol Cancer Ther 16: 1102–1113. doi: 10.1158/1535-7163.MCT-16-0314
![]() |
[34] |
Chan DV, Sharma R, Ju CYA, et al. (2013) A recombinant scFv-FasLext as a targeting cytotoxic agent against human Jurkat-Ras cancer. J Biomed Sci 20: 16. doi: 10.1186/1423-0127-20-16
![]() |
[35] |
Hemmerle T, Hess C, Venetz D, et al. (2014) Tumor targeting properties of antibody fusion proteins based on different members of the murine tumor necrosis superfamily. J Biotechnol 172: 73–76. doi: 10.1016/j.jbiotec.2013.12.010
![]() |
[36] | Orbach A, Rachmilewitz J, Shani N, et al. (2010) CD40.FasL and CTLA-4.FasL fusion proteins induce apoptosis in malignant cell lines by dual signaling. Am J Pathol 177: 3159–3168. |
[37] |
Aronin A, Amsili S, Progozhina T, et al. (2014) Highly efficient in-vivo Fas-mediated apoptosis of B-cell lymphoma by hexameric CTLA4-FasL. J Hematol Oncol 7: 64. doi: 10.1186/s13045-014-0064-6
![]() |
[38] |
Zhang W, Wang B, Wang F, et al. (2012) CTLA4-FasL fusion product suppresses proliferation of fibroblast-like synoviocytes and progression of adjuvant-induced arthritis in rats. Mol Immunol 50: 150–159. doi: 10.1016/j.molimm.2012.01.007
![]() |
[39] |
Shi W, Chen M, Xie L (2007) Prolongation of corneal allograft survival by CTLA4-FasL in a murine model. Graef Arch Clin Exp 245: 1691–1697. doi: 10.1007/s00417-007-0606-5
![]() |
[40] |
Feng YG, Jin YZ, Zhang QY (2005) CTLA4-Fas ligand gene transfer mediated by adenovirus induce long-time survival of murine cardiac allografts. Transpl P 37: 2379–2381. doi: 10.1016/j.transproceed.2005.03.022
![]() |
[41] |
Kitano H, Mamiya A, Kokubun S, et al. (2012) Efficient nonviral gene therapy with FasL and Del1 fragments in mice. J Gene Med 14: 642–650. doi: 10.1002/jgm.2682
![]() |
[42] |
Morello A, Daburon S, Castroviejo M, et al. (2013) Enhancing production and cytotoxic activity of polymeric soluble FasL-based chimeric proteins by concomitant expression of soluble FasL. Plos One 8: e73375. doi: 10.1371/journal.pone.0073375
![]() |
[43] |
Franke DDH, Yolcu ES, Alard P, et al. (2007) A novel multimeric form of FasL modulates the ability of diabetogenic T cells to mediate type 1 diabetes in an adoptive transfer model. Mol Immunol 44: 2884–2892. doi: 10.1016/j.molimm.2007.01.014
![]() |
[44] |
Cereghino JL, Cregg JM (2000) Heterologous protein expression in the methylotrophic yeast Pichia pastoris. FEMS Microbiol Rev 24: 45–66. doi: 10.1111/j.1574-6976.2000.tb00532.x
![]() |
[45] |
Daly R, Hearn MTW (2005) Expression of heterologous proteins in Pichia pastoris: a useful experimental tool in protein engineering and production. J Mol Recogit 18: 119–138. doi: 10.1002/jmr.687
![]() |
[46] |
Ahmad M, Hirtz M, Pichler H, et al. (2014) Protein expression in Pichia pastoris: recent achievements and perspectives for heterologous protein production. Appl Microbiol Biot 98: 5301–5317. doi: 10.1007/s00253-014-5732-5
![]() |
[47] |
Muraki M (2014) Improved production of recombinant human Fas ligand extracellular domain in Pichia pastoris: yield enhancement using disposable culture-bag and its application to site-specific chemical modifications. BMC Biotechnol 14: 19. doi: 10.1186/1472-6750-14-19
![]() |
[48] |
Jacobs PP, Geysens S, Vervecken W, et al. (2009) Engineering complex-type N-glycosylation in Pichia pastoris using glycoswitch technology. Nat Protoc 4: 58–70. doi: 10.1038/nprot.2008.213
![]() |
[49] |
Helenius A, Aebi M (2004) Roles of N-linked glycans in endoplasmic reticulum. Annu Rev Biochem 73: 1019–1049. doi: 10.1146/annurev.biochem.73.011303.073752
![]() |
[50] |
Pfeffer M, Maurer M, Stadlmann J, et al. (2012) Intracellular interactome of secreted antibody Fab fragment in Pichia pastoris reveals its routes of secretion and degradation. Appl Microbiol Biot 93: 2503–2512. doi: 10.1007/s00253-012-3933-3
![]() |
[51] | Muraki M (2008) Improved secretion of human Fas ligand extracellular domain by N-terminal part truncation in Pichia pastoris and preparation of the N-linked carbohydrate chain trimmed derivative. Protein Expres Purif 60: 205–213. |
[52] | Orlinick JR, Elkon KB, Chao MV (1997) Separate domains of the human Fas ligand dictate self-association and receptor binding. J Biol Chem 51: 32221–32229. |
[53] | Gasteiger E, Hoogland C, Gattiker A, et al. (2005) Protein identification and analysis tools on the ExPASy server, In: Walker JM, The Proteomics Protocols Handbook, Totowa: Humana Press, 571–607. |
[54] |
Muraki M, Hirota K (2017) Site-specific chemical conjugation of human Fas ligand extracellular domain using trans-cyclooctene-methyltetrazine reactions. BMC Biotechnol 17: 56. doi: 10.1186/s12896-017-0381-2
![]() |
[55] |
Mahiou J, Abastado JP, Cabanie L, et al. (1998) Soluble FasR ligand-binding domain: high-yield production of active fusion and non-fusion recombinant proteins using the baculovirus/insect cell system. Biochem J 330: 1051–1058. doi: 10.1042/bj3301051
![]() |
[56] |
Muraki M, Honda S (2010) Efficient production of human Fas receptor extracellular domain-human IgG1 heavy chain Fc domain fusion protein using baculovirus/silkworm expression system. Protein Expres Purif 73: 209–216. doi: 10.1016/j.pep.2010.05.007
![]() |
[57] |
Muraki M, Honda S (2011) Improved isolation and purification of functional human Fas receptor extracellular domain using baculovirus-silkworm expression system. Protein Expres Purif 80: 102–109. doi: 10.1016/j.pep.2011.07.002
![]() |
[58] |
Vogl T, Glieder A (2013) Regulation of Pichia pastoris promoters and its consequences for protein production. New Biotechnol 30: 385–404. doi: 10.1016/j.nbt.2012.11.010
![]() |
[59] | Allais JJ, Louktibi A, Baratti J (1980) Oxidation of methanol by the yeast, Pichia pastoris. Purification and properties of the alcohol oxidase. Agric Biol Chem 44: 2279–2289. |
[60] | Muraki M (2014) Secretory production of recombinant proteins in methylotrophic yeast Pichia pastoris using a disposable culture-bag. PSSJ Arch 7: e078. |
[61] |
Vanamee ÉS, Faustmann DL (2018) Structural principles of tumor necrosis factor superfamily signaling. Sci Signal 11: eaao4910. doi: 10.1126/scisignal.aao4910
![]() |
[62] | Hermanson GT (2013) Chapter 10: Fluorescent Probes, In: Bioconjugate techniques (Third Ed.), London: Academic Press, 395–463. |
[63] |
Wu H, Devaraj NK (2016) Inverse electron-demand Diels-Alder biorthogonal reactions. Top Curr Chem 374: 3. doi: 10.1007/s41061-015-0005-z
![]() |
[64] | Mayer S, Lang K (2017) Tetrazines in inverse-electron-demand Diels-Alder cycloadditions and their use in biology. Synthesis-Stuttgart 49: 830–848. |
[65] |
Muraki M (2016) Preparation of a functional fluorescent human Fas ligand extracellular domain derivative using a three-dimensional structure guided site-specific fluorochrome conjugation. SpringerPlus 5: 997. doi: 10.1186/s40064-016-2673-8
![]() |
[66] |
Ogasawara J, Watanabe-Fukunaga R, Adachi M, et al. (1993) Lethal effect of the anti-Fas antibody in mice. Nature 364: 806–809. doi: 10.1038/364806a0
![]() |
[67] |
Wajant H, Gerspach J, Pfizenmaier K (2013) Engineering death receptor ligands for cancer therapy. Cancer Lett 332: 163–174. doi: 10.1016/j.canlet.2010.12.019
![]() |
[68] |
Villa-Morales M, Fernández-Piqueras J (2012) Targeting the Fas/FasL signaling pathway in cancer therapy. Expert Opin Ther Tar 16: 85–101. doi: 10.1517/14728222.2011.628937
![]() |
[69] |
Oliveira BL, Guo Z, Bernardes GJL (2017) Inverse electron demand Diels-Alder reactions in chemical biology. Chem Soc Rev 46: 4895–4950. doi: 10.1039/C7CS00184C
![]() |
[70] | Green NM (1963) Avidin. 4. Stability at extremes of pH and dissociation into sub-units by guanidine hydrochloride. Biochem J 89: 609–620. |
[71] | Paganelli G, Magnani P, Zito F, et al. (1991) Three-step monoclonal antibody tumor targeting in carcinoembryonic antigen positive patients. Cancer Res 51: 5960–5966. |
[72] | Penichet ML, Kang YS, Pardridge WM, et al. (1999) An antibody-avidin fusion protein specific for the transferrin receptor serves as a delivery vehicle for effective brain targeting: initial applications in anti-HIV antisense drug delivery to brain. J Immunol 163: 4421–4426. |
[73] | Schultz J, Lin Y, Sanderson J, et al. (2000) A tetravalent single-chain antibody-streptavidin fusion protein for pretargeted lymphoma therapy. Cancer Res 60: 6663–6669. |
[74] |
Mohsin H, Jia F, Bryan JN, et al. (2011) Comparison of pretargeted and conventional CC49 radioimmunotherapy using 149Pm, 166Ho, and 177Lu. Bioconjugate Chem 22: 2444–2452. doi: 10.1021/bc200258x
![]() |
[75] |
Micheau O, Solary E, Hammann A, et al. (1997) Sensitization of cancer cells treated with cytotoxic drugs to Fas-mediated cytotoxity. J Natl CancerI 89: 783–789. doi: 10.1093/jnci/89.11.783
![]() |
[76] |
Yang D, Torres CM, Bardhan K, et al. (2012) Decitabine and vorinostat cooperate to sensitize colon carcinoma cells to Fas ligand-induced apoptosis in vitro and tumor suppression in vivo. J Immunol 188: 4441–4449. doi: 10.4049/jimmunol.1103035
![]() |
[77] |
Galenkamp KMO, Carriba P, Urresti J, et al. (2015) TNFα sensitizes neuroblastoma cells to FasL-, cisplatin- and etoposide-induced cell death by NF-ΚB-mediated expression of Fas. Mol Cancer 14: 62. doi: 10.1186/s12943-015-0329-x
![]() |
[78] | Xu X, Fu XY, Plate J (1998) IFN-γ induces cell growth inhibition by Fas-mediated apoptosis: requirement of STAT1 protein for up-regulation of Fas and FasL expression. Cancer Res 58: 2832–2837. |
[79] |
Horton JK, Siamakpour-Reihani S, Lee CT, et al. (2015) Fas death receptor: a breast cancer subtype-specific radiation response biomarker and potential therapeutic target. Radiat Res 184: 456–469. doi: 10.1667/RR14089.1
![]() |
[80] |
Tamakoshi A, Nakachi K, Ito Y, et al. (2008) Soluble Fas level and cancer mortality: findings from a nested case-control study within a large-scale prospective study. Int J Cancer 123: 1913–1916. doi: 10.1002/ijc.23731
![]() |
[81] |
Bhatraju PK, Robinson-Cohen C, Mikacenic C, et al. (2017) Circulating levels of soluble Fas (sCD95) are associated with risk for development of a nonresolving acute kidney injury subphenotype. Crit Care 21: 217. doi: 10.1186/s13054-017-1807-x
![]() |
[82] |
Hamilton SR, Gerngross TU (2007) Glycosylation engineering in yeast: the advent of fully humanized yeast. Curr Opin Biotech 18: 387–392. doi: 10.1016/j.copbio.2007.09.001
![]() |
[83] |
Liu L, Stadheim A, Hamuro L, et al. (2011) Pharmacokinetics of IgG1 monoclonal antibodies produced in humanized Pichia pastoris with specific glycoforms: a comparative study with CHO produced materials. Biologicals 39: 205–210. doi: 10.1016/j.biologicals.2011.06.002
![]() |
1. | Mona M. Saber, Nada Monir, Azza S. Awad, Marwa E. Elsherbiny, Hala F. Zaki, TLR9: A friend or a foe, 2022, 307, 00243205, 120874, 10.1016/j.lfs.2022.120874 |